Skip to search formSkip to main contentSkip to account menu

RX-3117

Known as: Cytidine Analog RX-3117 
An orally available small molecule and nucleoside antimetabolite with potential antineoplastic activity. Upon administration, the cytidine analog RX… 
National Institutes of Health

Related topics

Related topics

5 relations
DNA Synthesis InhibitionNucleotide BiosynthesisPositive Regulation of ApoptosisRibonucleotide Reductase

Broader (1)

fluorocyclopentenylcytosine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Abstract 428: Phenotyping pancreatic cancer CTCs as biomarkers for RX-3117 clinical trials
Background: RX-3117 is an oral, small molecule nucleoside analogue pro-drug being used in combination with nab-paclitaxel in a… 
Review
2019
Review
2019
A phase I/II study of RX-3117, an oral antimetabolite nucleoside, in combination with nab-paclitaxel (nab-pac) as first-line treatment of metastatic pancreatic cancer (met-PC): Preliminary results.
420 Background: RX-3117 is an oral small molecule antimetabolite, cyclopentyl pyrimidyl nucleoside that is activated by cancer… 
2019
2019
Abstract 1267: Unusual mechanism of resistance to the novel cytidine analog fluorocyclopentenylcytosine (RX-3117)
RX-3117 is a novel cytidine analog showing encouraging results in ongoing Phase 2a studies with gemcitabine-resistant pancreatic… 
2018
2018
Preliminary results from an ongoing phase 2a study of RX-3117, an oral nucleoside analogue to treat advanced urothelial cancer (aUC).
4543Background: RX-3117 is an oral small molecule nucleoside analogue (cyclopentyl pyrimidyl nucleoside) that is activated by… 
2017
2017
Abstract 1790: Evaluation of UCK2 protein expression as a potential predictive biomarker of RX-3117
Background: A novel, orally bioavailable nucleoside analogue, RX-3117, is a prodrug activated intracellularly by Uridine Cytidine… 
2016
2016
The radiosensitizing effect of fluorocyclopentenyl-cytosine (RX-3117) in ovarian and lung cancer cell lines
ABSTRACT RX-3117 (fluorocyclopentenyl-cytosine) is a novel cytidine analog currently being evaluated in a Phase Ib clinical trial… 
2016
2016
Sensitive liquid chromatography mass spectrometry (LC-MS) assay reveals novel insights on DNA methylation and incorporation of gemcitabine, its metabolite difluorodeoxyuridine, deoxyuridine, and RX…
ABSTRACT Antimetabolites are incorporated into DNA and RNA, affecting their function. Liquid-chromatography-mass-spectrometry (LC… 
2015
2015
A phase 1 exploratory study of RX-3117 to determine oral bioavailability in cancer subjects with solid tumors.
e13545 Background: RX-3117 (fluorocyclopentenylcytosine) is a novel antimetabolite, that requires activation by uridine-cytidine… 
2015
2015
Abstract 2622: Fluorocyclopentenylcytosine (RX-3117) is activated by uridine-cytidine kinase 2, a potential biomarker
Fluorocyclopentenylcytosine (RX-3117) is an orally bioavailable novel cytidine analog, currently being tested in a Phase I… 
2014
2014
A novel cytidine analog, RX-3117, shows potent efficacy in xenograft models, even in tumors that are resistant to gemcitabine.
RX-3117 (fluorocyclopentenylcytosine) is a cytidine analog and this class of drugs, including gemcitabine, has been widely used… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)